Selected Adverse Events Reported after COVID-19 Vaccination

Multiple studies and reviews of data from vaccine safety monitoring systems continue to show that vaccines are safe. As a result, the agency will refocus enhanced surveillance and safety monitoring efforts toward children and adolescents.

As of September 22, 2022, there have been 1,028 preliminary reports in VAERS among people younger than age 18 years under review for potential cases of myocarditis and pericarditis. Of these, 257 remain under review. Through confirmation of symptoms and diagnostics by provider interview or review of medical records, 679 reports have been verified to meet CDC’s working case definition for myocarditis. See below for counts of verified reports of myocarditis by age group.

5-11 years: 22 verified reports of myocarditis after 21,380,593 doses administered

12-15 years: 352 verified reports of myocarditis after 24,420,543 doses administered

16-17 years: 305 verified reports of myocarditis after 13,385,065 doses administered

As the COVID-19 vaccines are authorized for younger children, CDC and FDA will continue to monitor for and evaluate reports of myocarditis and pericarditis after COVID-19 vaccination and will share more information as it becomes available. Learn more about myocarditis and pericarditis, including clinical considerations, after mRNA COVID-19 vaccination.